Evidence map›Paper›PMID 25692914›Full record

ArticleThe New England journal of medicine2015

Treatment choice for diabetic macular edema.

Daniel F Martin, Maureen G Maguire

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.The Journal of clinical endocrinology and metabolism · 2019
    Guideline
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Ophthalmic community perception of new medication needs.International journal of ophthalmology · 2018
    Article
  9. Article
  10. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  11. Review
  12. Off-label use of targeted therapies in oncology.World journal of clinical oncology · 2016
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Daniel F MartinFrom the Cleveland Clinic Cole Eye Institute, Cleveland (D.F.M.); and the Department of Ophthalmology, University of Pennsylvania, Philadelphia (M.G.M.).
Maureen G Maguire

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedBevacizumabDiabetic RetinopathyFemaleHumansMacular EdemaMaleRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AVisual AcuityafliberceptAntibodies, Monoclonal, HumanizedBevacizumabRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor A

Identifiers

PMID25692914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.